Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Eunheiu Jeong  (Jeong E) 1 Article
Various Oscillation Patterns of Serum Fibroblast Growth Factor 21 Concentrations in Healthy Volunteers
Sang Ah Lee, Eunheiu Jeong, Eun Hee Kim, Mi-Seon Shin, Jenie Yoonoo Hwang, Eun Hee Koh, Woo Je Lee, Joong-Yeol Park, Min-Seon Kim
Diabetes Metab J. 2012;36(1):29-36.   Published online February 17, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.1.29
  • 3,935 View
  • 34 Download
  • 13 Crossref
AbstractAbstract PDFPubReader   
Background

Fibroblast growth factor 21 (FGF21) was originally identified as a paroxysm proliferator activated receptor-α target gene product and is a hormone involved in metabolic regulation. The purpose of this study was to investigate the diurnal variation of serum FGF21 concentration in obese and non-obese healthy volunteers.

Methods

Blood samples were collected from five non-obese (body mass index [BMI] ≤23 kg/m2) and five obese (BMI ≥25 kg/m2) healthy young men every 30 to 60 minutes over 24 hours. Serum FGF21 concentrations were determined by radioimmunoassay. Anthropometric parameters, glucose, free fatty acid, insulin, leptin, and cortisol concentrations were also measured.

Results

The serum FGF21 concentrations displayed various individual oscillation patterns. The oscillation frequency ranged between 6 and 12 times per day. The average duration of oscillation was 2.52 hours (range, 1.9 to 3.0 hours). The peaks and troughs of FGF21 oscillation showed no circadian rhythm. However, the oscillation frequency had a diurnal variation and was lower during the light-off period than during the light-on period (2.4 vs. 7.3 times, P<0.001). There was no difference in the total frequency or duration of oscillations between non-obese and obese subjects, but obese individuals had increased numbers of larger oscillations (amplitude ≥0.19 ng/mL).

Conclusion

Various oscillation patterns in serum FGF21 concentration were observed, and reduced oscillation frequencies were seen during sleep. The oscillation patterns of serum FGF21 concentration suggest that FGF21 may be secreted into systemic circulation in a pulsatile manner. Obesity appeared to affect the amplitude of oscillations of serum FGF21.

Citations

Citations to this article as recorded by  
  • Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism
    Zhenning Yang, Helmut Zarbl, Grace L. Guo
    Molecular Pharmacology.2024; 105(3): 179.     CrossRef
  • Acute sleep loss alters circulating fibroblast growth factor 21 levels in humans: A randomised crossover trial
    Luiz Eduardo Mateus Brandão, Daniel Espes, Jakub Orzechowski Westholm, Teemu Martikainen, Nestori Westerlund, Lauri Lampola, Alexandru Popa, Heike Vogel, Annette Schürmann, Suzanne L. Dickson, Christian Benedict, Jonathan Cedernaes
    Journal of Sleep Research.2022;[Epub]     CrossRef
  • Metabolic Stress Index Including Mitochondrial Biomarker for Noninvasive Diagnosis of Hepatic Steatosis
    Jae Seung Chang, Jhii-Hyun Ahn, Seong Hee Kang, Sang-Baek Koh, Jang-Young Kim, Soon Koo Baik, Ji Hye Huh, Samuel S. Lee, Moon Young Kim, Kyu-Sang Park
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Single-Arm 8-Week Ad Libitum Self-Prepared Paleo Diet Reduces Cardiometabolic Disease Risk Factors in Overweight Adults
    Melissa M. Markofski, Kristofer Jennings, Chad Dolan, Natalie A. Davies, Emily C. LaVoy, Edward J. Ryan, Andres E. Carrillo
    American Journal of Lifestyle Medicine.2021; 15(6): 690.     CrossRef
  • Diurnal rhythm in clinical chemistry: An underrated source of variation
    Mohamed Abou El Hassan, Edgard Delvin, Manal O. Elnenaei, Barry Hoffman
    Critical Reviews in Clinical Laboratory Sciences.2018; 55(8): 516.     CrossRef
  • Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity
    Antero Salminen, Kai Kaarniranta, Anu Kauppinen
    Cellular Signalling.2017; 40: 10.     CrossRef
  • Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
    Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta
    Nature Reviews Drug Discovery.2016; 15(1): 51.     CrossRef
  • Response of fibroblast growth factor 21 to meal intake and insulin infusion in patients on maintenance haemodialysis
    Mark Reinhard, Jan Frystyk, Bente Jespersen, Else Randers, Bo Martin Bibby, Per Ivarsen
    Clinical Endocrinology.2015; 83(2): 187.     CrossRef
  • Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE−/− mice
    Xi Wu, Yong-Fen Qi, Jin-Rui Chang, Wei-Wei Lu, Jin-Sheng Zhang, Shao-Ping Wang, Shu-Juan Cheng, Ming Zhang, Qian Fan, Yuan Lv, Hui Zhu, Man-Kun Xin, Yun Lv, Jing-Hua Liu
    Heart and Vessels.2015; 30(5): 657.     CrossRef
  • Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal
    Bo Angelin, Tobias E. Larsson, Mats Rudling
    Cell Metabolism.2012; 16(6): 693.     CrossRef
  • Metabolic actions of fibroblast growth factor 21
    Daniel Cuevas-Ramos, Carlos A. Aguilar-Salinas, Francisco J. Gómez-Pérez
    Current Opinion in Pediatrics.2012; 24(4): 523.     CrossRef
  • Fibroblast Growth Factor 21: A Novel Metabolic Regulator
    Ji A Seo, Nan Hee Kim
    Diabetes & Metabolism Journal.2012; 36(1): 26.     CrossRef
  • MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21
    Pedro Iglesias, Rafael Selgas, Sara Romero, Juan J Díez
    European Journal of Endocrinology.2012; 167(3): 301.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer